Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-HIV Agents | 10 | 2015 | 1324 | 1.220 |
Why?
|
Malaria | 3 | 2024 | 213 | 1.140 |
Why?
|
Child Mortality | 9 | 2024 | 96 | 1.070 |
Why?
|
HIV Infections | 19 | 2023 | 5097 | 1.060 |
Why?
|
Humans | 43 | 2024 | 14537 | 0.930 |
Why?
|
Hepatitis B Vaccines | 1 | 2024 | 40 | 0.920 |
Why?
|
Cause of Death | 9 | 2024 | 221 | 0.910 |
Why?
|
Child | 15 | 2024 | 2242 | 0.880 |
Why?
|
Hepatitis B | 1 | 2024 | 125 | 0.830 |
Why?
|
South Africa | 27 | 2024 | 7596 | 0.800 |
Why?
|
Infant | 17 | 2024 | 2244 | 0.790 |
Why?
|
Adult | 21 | 2024 | 5913 | 0.790 |
Why?
|
Male | 28 | 2024 | 6754 | 0.770 |
Why?
|
Rural Health Services | 2 | 2013 | 48 | 0.750 |
Why?
|
Female | 32 | 2024 | 9103 | 0.750 |
Why?
|
Anti-Retroviral Agents | 4 | 2013 | 551 | 0.720 |
Why?
|
Child, Preschool | 13 | 2024 | 1748 | 0.700 |
Why?
|
Adolescent | 13 | 2024 | 2985 | 0.660 |
Why?
|
Young Adult | 11 | 2024 | 2498 | 0.640 |
Why?
|
Middle Aged | 11 | 2024 | 3601 | 0.620 |
Why?
|
Seroepidemiologic Studies | 3 | 2023 | 109 | 0.590 |
Why?
|
Rural Population | 8 | 2014 | 654 | 0.570 |
Why?
|
Infant, Newborn | 11 | 2024 | 1479 | 0.560 |
Why?
|
Prevalence | 5 | 2024 | 1192 | 0.470 |
Why?
|
Aged | 6 | 2024 | 1740 | 0.460 |
Why?
|
Health Status | 2 | 2013 | 111 | 0.440 |
Why?
|
Epidemics | 1 | 2014 | 65 | 0.440 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 57 | 0.440 |
Why?
|
Treatment Refusal | 1 | 2013 | 13 | 0.430 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2015 | 472 | 0.430 |
Why?
|
Healthcare Disparities | 1 | 2013 | 43 | 0.430 |
Why?
|
Cytokines | 1 | 2013 | 107 | 0.420 |
Why?
|
Ambulatory Care | 1 | 2013 | 54 | 0.420 |
Why?
|
Lost to Follow-Up | 1 | 2013 | 62 | 0.420 |
Why?
|
Perinatal Death | 2 | 2022 | 33 | 0.400 |
Why?
|
Child Health | 5 | 2024 | 77 | 0.390 |
Why?
|
HIV | 1 | 2014 | 380 | 0.380 |
Why?
|
CD4 Lymphocyte Count | 8 | 2015 | 656 | 0.380 |
Why?
|
Retrospective Studies | 2 | 2024 | 799 | 0.370 |
Why?
|
Health Services Accessibility | 1 | 2013 | 280 | 0.360 |
Why?
|
Stillbirth | 4 | 2024 | 83 | 0.360 |
Why?
|
Immunoglobulin G | 2 | 2022 | 231 | 0.350 |
Why?
|
Quality of Health Care | 1 | 2010 | 62 | 0.340 |
Why?
|
Antibodies, Viral | 2 | 2022 | 284 | 0.340 |
Why?
|
Cohort Studies | 6 | 2015 | 967 | 0.320 |
Why?
|
Age Distribution | 2 | 2024 | 107 | 0.320 |
Why?
|
Infant Mortality | 3 | 2024 | 97 | 0.290 |
Why?
|
Incidence | 3 | 2023 | 685 | 0.290 |
Why?
|
Corynebacterium diphtheriae | 2 | 2017 | 9 | 0.290 |
Why?
|
Diphtheria | 2 | 2017 | 16 | 0.280 |
Why?
|
HIV-1 | 2 | 2015 | 1260 | 0.280 |
Why?
|
Disease Outbreaks | 2 | 2017 | 111 | 0.270 |
Why?
|
Malnutrition | 2 | 2024 | 56 | 0.270 |
Why?
|
Africa South of the Sahara | 4 | 2024 | 353 | 0.260 |
Why?
|
Respiratory Tract Infections | 2 | 2021 | 266 | 0.260 |
Why?
|
Pregnancy | 6 | 2024 | 1862 | 0.250 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 1422 | 0.250 |
Why?
|
Population Surveillance | 4 | 2021 | 325 | 0.240 |
Why?
|
Diagnostic Errors | 1 | 2024 | 18 | 0.230 |
Why?
|
Communicable Diseases, Imported | 1 | 2024 | 3 | 0.230 |
Why?
|
Regression Analysis | 2 | 2014 | 133 | 0.220 |
Why?
|
Neural Tube Defects | 1 | 2023 | 6 | 0.220 |
Why?
|
Treatment Outcome | 4 | 2014 | 889 | 0.210 |
Why?
|
Cross Infection | 1 | 2023 | 52 | 0.210 |
Why?
|
Pneumonia | 1 | 2024 | 131 | 0.200 |
Why?
|
Hepatitis B virus | 1 | 2024 | 157 | 0.200 |
Why?
|
Africa | 3 | 2024 | 376 | 0.200 |
Why?
|
Public Health Surveillance | 1 | 2022 | 52 | 0.200 |
Why?
|
Infant Health | 1 | 2021 | 16 | 0.190 |
Why?
|
Pneumococcal Vaccines | 1 | 2024 | 278 | 0.190 |
Why?
|
Developing Countries | 1 | 2024 | 400 | 0.190 |
Why?
|
Registries | 2 | 2019 | 91 | 0.190 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 101 | 0.190 |
Why?
|
Vital Statistics | 1 | 2021 | 10 | 0.180 |
Why?
|
Diarrhea | 1 | 2021 | 76 | 0.180 |
Why?
|
Health Behavior | 1 | 2021 | 79 | 0.180 |
Why?
|
Meningitis, Cryptococcal | 2 | 2011 | 16 | 0.180 |
Why?
|
Asymptomatic Infections | 1 | 2020 | 34 | 0.170 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 115 | 0.170 |
Why?
|
Socioeconomic Factors | 4 | 2013 | 411 | 0.170 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2021 | 155 | 0.160 |
Why?
|
Vaccination Coverage | 1 | 2019 | 13 | 0.160 |
Why?
|
Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
Politics | 1 | 2019 | 24 | 0.160 |
Why?
|
Autopsy | 3 | 2024 | 140 | 0.160 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2021 | 200 | 0.150 |
Why?
|
Delivery of Health Care | 2 | 2022 | 239 | 0.130 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 529 | 0.120 |
Why?
|
Body Weight | 1 | 2015 | 111 | 0.120 |
Why?
|
Causality | 1 | 2014 | 7 | 0.120 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 6 | 0.120 |
Why?
|
Data Interpretation, Statistical | 1 | 2014 | 22 | 0.120 |
Why?
|
Longevity | 1 | 2014 | 14 | 0.120 |
Why?
|
Age Factors | 4 | 2021 | 370 | 0.120 |
Why?
|
Models, Statistical | 1 | 2014 | 55 | 0.120 |
Why?
|
Ethiopia | 2 | 2024 | 18 | 0.110 |
Why?
|
Risk Factors | 5 | 2021 | 1475 | 0.110 |
Why?
|
Viral Load | 2 | 2015 | 819 | 0.110 |
Why?
|
Morbidity | 1 | 2013 | 37 | 0.110 |
Why?
|
Patient Compliance | 1 | 2014 | 120 | 0.110 |
Why?
|
Amphotericin B | 2 | 2011 | 10 | 0.110 |
Why?
|
Fluconazole | 2 | 2011 | 17 | 0.110 |
Why?
|
Self Report | 1 | 2013 | 114 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2011 | 40 | 0.110 |
Why?
|
Demography | 1 | 2013 | 105 | 0.100 |
Why?
|
Disabled Persons | 1 | 2013 | 23 | 0.100 |
Why?
|
Health Services for the Aged | 1 | 2012 | 1 | 0.100 |
Why?
|
Health Status Indicators | 1 | 2012 | 17 | 0.100 |
Why?
|
Depression | 1 | 2013 | 121 | 0.100 |
Why?
|
Body Mass Index | 1 | 2013 | 321 | 0.100 |
Why?
|
Sex Factors | 4 | 2014 | 227 | 0.100 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 563 | 0.100 |
Why?
|
Medical Audit | 1 | 2010 | 26 | 0.090 |
Why?
|
Quality of Life | 1 | 2012 | 177 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 125 | 0.090 |
Why?
|
Obesity | 1 | 2013 | 367 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 35 | 0.080 |
Why?
|
Asia | 2 | 2021 | 72 | 0.080 |
Why?
|
Longitudinal Studies | 1 | 2010 | 435 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2011 | 256 | 0.080 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2010 | 195 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2013 | 468 | 0.070 |
Why?
|
Child Nutrition Disorders | 1 | 2024 | 13 | 0.060 |
Why?
|
Sierra Leone | 1 | 2024 | 11 | 0.060 |
Why?
|
Bangladesh | 1 | 2024 | 17 | 0.060 |
Why?
|
Mali | 1 | 2024 | 20 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2024 | 14 | 0.060 |
Why?
|
Mozambique | 1 | 2024 | 55 | 0.060 |
Why?
|
Meningitis | 1 | 2024 | 26 | 0.060 |
Why?
|
Meningitis, Bacterial | 1 | 2024 | 38 | 0.060 |
Why?
|
Tuberculosis | 1 | 2010 | 543 | 0.060 |
Why?
|
Kenya | 1 | 2024 | 183 | 0.060 |
Why?
|
Comorbidity | 1 | 2024 | 188 | 0.060 |
Why?
|
Asia, Southeastern | 1 | 2023 | 7 | 0.050 |
Why?
|
Folic Acid | 1 | 2023 | 12 | 0.050 |
Why?
|
Family | 1 | 2022 | 35 | 0.050 |
Why?
|
Global Burden of Disease | 1 | 2021 | 5 | 0.050 |
Why?
|
Prognosis | 2 | 2013 | 199 | 0.050 |
Why?
|
Mothers | 1 | 2023 | 195 | 0.050 |
Why?
|
Streptococcus pneumoniae | 1 | 2024 | 336 | 0.050 |
Why?
|
Africa, Southern | 1 | 2021 | 91 | 0.050 |
Why?
|
Urban Health | 1 | 2021 | 78 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
Research | 1 | 2020 | 65 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
Prenatal Care | 1 | 2020 | 147 | 0.040 |
Why?
|
Mass Screening | 1 | 2020 | 245 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
CRISPR-Cas Systems | 1 | 2017 | 6 | 0.040 |
Why?
|
Multilocus Sequence Typing | 1 | 2017 | 19 | 0.040 |
Why?
|
History, 21st Century | 1 | 2017 | 42 | 0.040 |
Why?
|
Whole Genome Sequencing | 1 | 2017 | 44 | 0.040 |
Why?
|
Genome, Viral | 1 | 2017 | 64 | 0.040 |
Why?
|
Immunization | 1 | 2017 | 63 | 0.030 |
Why?
|
Phylogeny | 1 | 2017 | 231 | 0.030 |
Why?
|
Models, Biological | 1 | 2015 | 77 | 0.030 |
Why?
|
Zambia | 1 | 2015 | 115 | 0.030 |
Why?
|
Treatment Failure | 1 | 2015 | 175 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2015 | 217 | 0.030 |
Why?
|
Poverty | 1 | 2015 | 152 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 156 | 0.030 |
Why?
|
Eligibility Determination | 1 | 2014 | 16 | 0.030 |
Why?
|
Interview, Psychological | 1 | 2013 | 6 | 0.030 |
Why?
|
Depressive Disorder, Major | 1 | 2013 | 20 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 163 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2013 | 41 | 0.030 |
Why?
|
Uganda | 1 | 2013 | 197 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2012 | 22 | 0.020 |
Why?
|
RNA, Viral | 1 | 2013 | 303 | 0.020 |
Why?
|
Chronic Disease | 1 | 2012 | 107 | 0.020 |
Why?
|
Logistic Models | 1 | 2012 | 254 | 0.020 |
Why?
|
Databases, Factual | 1 | 2010 | 64 | 0.020 |
Why?
|
Survival Analysis | 1 | 2010 | 149 | 0.020 |
Why?
|
Data Collection | 1 | 2010 | 86 | 0.020 |
Why?
|
Prospective Studies | 1 | 2010 | 1160 | 0.020 |
Why?
|